Page last updated: 2024-11-07

fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether: structure CF2=C(CF3)OCH2F; a vinyl ether [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID105015
CHEBI ID190039
SCHEMBL ID2537811
MeSH IDM0210965

Synonyms (22)

Synonym
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether
1-propene, 1,1,3,3,3-pentafluoro-2-(fluoromethoxy)-
2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene
pentafluoroisopropenyl fluoromethyl ether
1,1,3,3,3-pentafluoro-2-(fluoromethoxy)-1-propene
1-propene, 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-
fluoromethyl pentafluoroprop-1-en-2-yl ether
CHEBI:190039
2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound a)
58109-34-5
1,1,3,3,3-pentaluoro-2-(luoromethoxy)prop-1-ene
1,1,3,3,3-pentafluoro-2-(fluoromethoxy)prop-1-ene
unii-d4ony53p0n
d4ony53p0n ,
fluoromethyl 1,1,1,3,3-pentafluoro-2-propenyl ether
SCHEMBL2537811
fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether
DTXSID10973690
1,1,1,3,3-pentafluoroisopropenyl fluoromethyl ether
sevoflurane impurity a [ep impurity]
EN300-1663583
Z1255450533

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Although dose-related, neither the lethal nor the toxic effects are simply a function of cumulative dose (concentration-time)."( Toxicity of compound A in rats. Effect of increasing duration of administration.
Eger, EI; Ferrell, LD; Gonsowski, CT; Kerschmann, RL; Laster, MJ, 1994
)
0.29
"Soda lime converts sevoflurane to CF2 = C(CF3)OCH2F, an olefin called compound A, whose toxicity raises concerns regarding the safe administration of sevoflurane via rebreathing circuits."( Toxicity of compound A in rats. Effect of a 3-hour administration.
Eger, EI; Ferrell, LD; Gonsowski, CT; Kerschmann, RL; Laster, MJ, 1994
)
0.29
" Moderate duration low-flow sevoflurane anesthesia, during which compound A formation occurs, appears to be as safe as low-flow isoflurane anesthesia."( Assessment of low-flow sevoflurane and isoflurane effects on renal function using sensitive markers of tubular toxicity.
Artru, A; Bowdle, TA; Frink, EJ; Kharasch, ED; Nogami, WM; Zager, R, 1997
)
0.3
"Carbon dioxide absorbents degrade both halothane and sevoflurane to toxic unsaturated compounds (CF2=CBrCl and CH2F-O-C[=CF2][CF3] [i."( Quantitative differences in the production and toxicity of CF2=BrCl versus CH2F-O-C(=CF2)(CF3) (compound A): the safety of halothane does not indicate the safety of sevoflurane.
Eger, EI; Gong, D; Ionescu, P; Kerschmann, RL; Laster, MJ; Weiskopf, RB, 1997
)
0.3
" Although the toxicity of this compound was originally hypothesized to result from the biotransformation of its cysteine conjugates into toxic thionoacyl halide metabolites by renal cysteine conjugate beta-lyase, recent evidence suggests that alternative mechanisms may be responsible for compound A nephrotoxicity."( Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
Borkowf, CB; Marchick, MR; Martin, JL; Njoku, DB; Pohl, LR; Sokoloski, EA, 1999
)
0.3
" Recent advances in nephrotoxicity are molecular cloning of several transporters related to important toxic compounds in the kidney."( Recent advances in molecular mechanisms of nephrotoxicity.
Endou, H, 1998
)
0.3
" These studies show that Compound A is directly toxic to the liver, possibly via P 450 activation, and Compound A can react with sulfhydryls directly to produce a nephrotoxic."( Toxicity of a sevoflurane degradation product incubated with rat liver and renal cortical slices.
Catania, JM; Gandolfi, AJ; Parrish, AR, 2001
)
0.31
" Until recently, inorganic fluoride has been thought to be the aetiological agent responsible for fluorinated anaesthetic nephrotoxicity, with a toxic concentration threshold of 50 micromol/L in serum."( Renal toxicity with sevoflurane: a storm in a teacup?
Gentz, BA; Malan, TP, 2001
)
0.31
" Compound A is toxic in vivo with the kidney being the primary target."( Toxicity of compound A to C6 rat glioma cells.
Kofke, WA; Konat, GW; Miric, S, 2003
)
0.32
" FDVE-mercapturic acid sulfoxides were more toxic than other FDVE conjugates to renal proximal tubular cells in culture."( Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
Altuntas, TG; Kharasch, ED; Liggitt, HD; Schroeder, JL; Sheffels, P, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
"Fischer 344 rats underwent 3 h of nose-only exposure to compound A (0-220 ppm in initial dose-response experiments and 100-109 ppm in subsequent inhibitor experiments)."( Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
Hankins, DC; Hoffman, GM; Kharasch, ED; Kilty, CG; Thorning, D, 1998
)
0.3
"We examined the dose-response relationship of sevoflurane/Compound A and urinary excretion of albumin, glucose, and alpha-GST."( Dose of compound A, not sevoflurane, determines changes in the biochemical markers of renal injury in healthy volunteers.
Afshar, M; Cantillo, J; Deal, E; Goldberg, ME; Gratz, I; Larijani, G; McDougall, R; Vekeman, D; Zafeiridis, A, 1999
)
0.3
" After intravenous dosing with either diazepam or compound A, rats were anesthetized and blood was collected, then the brain was removed following no perfusion or whole-body perfusion with saline."( Comparison of the effects of perfusion in determining brain penetration (brain-to-plasma ratios) of small molecules in rats.
Anderson, LC; Colwell, L; Fenyk-Melody, JE; Peng, Q; Pikounis, W; Pivnichny, J; Shen, X; Tamvakopoulos, CS, 2004
)
0.32
"The microwave assisted extraction (MAE) technique has been evaluated for the extraction of active pharmaceutical ingredients (API) from various solid dosage forms."( Microwave-assisted extraction of active pharmaceutical ingredient from solid dosage forms.
Di Maso, M; Hoang, TH; Kwong, E; Sharma, R; Susanto, D, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (133)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.50)18.7374
1990's61 (45.86)18.2507
2000's61 (45.86)29.6817
2010's5 (3.76)24.3611
2020's4 (3.01)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.32 (24.57)
Research Supply Index5.09 (2.92)
Research Growth Index6.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials23 (16.55%)5.53%
Reviews9 (6.47%)6.00%
Case Studies1 (0.72%)4.05%
Observational0 (0.00%)0.25%
Other106 (76.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis in Patients With Gastrointestinal Tumors: a Prospective, Randomized, Controlled, Double-blind, Phase III Clinical Study [NCT04988971]Phase 390 participants (Anticipated)Interventional2021-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]